Given our data demonstrating that the STING/IFN-I signaling axis directly suppresses osteoclast differentiation, it is likely that STING agonists are particularly protective against bone cancer-induced bone destruction due to direct effects (e.g. Inhibition of osteoclastogenesis) and indirect effects (e.g. reduced tumor burden). The gene discussed is STING1; the disease is neoplasm.